Background: This study evaluated sexual function in cervical cancer survivors after concurrent chemoradiotherapy.Methods: Study participants comprised survivors of locally advanced cervical cancer (stages IIB-IVA) who completed concurrent chemoradiotherapy along with intracavitary brachytherapy at least two years prior at Dr S.N.Medical College, Jodhpur, Rajasthan, India. We used the Female Sexual Function Index questionnaire to assess sexual function. The cut-off score of the Female Sexual Function Index that identified female sexual arousal disorder was 26.55. A score less than 26.55 indicated the presence of female sexual arousal disorder.Results: A total of 48 locally advanced cervical cancer survivors enrolled in the study. Survivors had a mean age of 46.5 years. All received chemoradiotherapy along with intracavitary brachytherapy. The average time for treatment was 53.5 days. Patients had an average score for sexual desire of 2, 2.3 for arousal, 2.3 for sexual satisfaction, and 2.1 for pain during intercourse. The overall average score was 11.84 (range: 3.2-19.5) with a cut-off of 26.55. All survivors suffered from female sexual arousal disorder.Conclusion: Cervical cancer survivors had decreased sexual function which indicated female sexual arousal disorder. Patient education and active treatment of complications related to cancer treatments is a must for improvement of sexual function among survivors. Long-term complications should be considered in terms of treatment planning and follow-up treatment to improve the quality of life of cancer survivors.